Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale. The study, conducted in partnership by researchers at Nemours Children’s Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.
“High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor. This research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient’s health,” said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children’s Health System and senior author of the study. “Unique approaches to target tumor cells with nanoparticle delivery systems hold promise for treatment of resistant tumors, such as the high risk neuroblastoma. We are hopeful that in the future, nanoparticles can be utilized to personalize care to patients and reduce the late effects of therapy.”
Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys. About 700 new cases of neuroblastoma are diagnosed each year in the United States and most cases appear in children younger than 5 years old. High-risk neuroblastoma is hard to cure and is more likely to become resistant to standard therapies or recur. These cancers are also associated with late effects after treatments have ended, including developmental delays, hearing loss, or other disabilities.
Curcumin has been shown to have substantial anti-cancer ability, but its low solubility and poor stability have made its use in medicinal applications challenging. Researchers from Nemours and UCF found that nanoparticles can be used to deliver curcumin to tumor sites.
“This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,” said Professor Sudipta Seal, who directs of UCF’s NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study. “More research is needed, but we are hopeful it could lead to more effective treatment of this devastating disease in the future.”
In the study, researchers loaded Cerium oxide nanoparticles with curcumin and coated them with dextran to test in cell lines of a high-risk form of neuroblastoma, known as MYCN-amplified, as well as non-amplified neuroblastoma. This formulation induced substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells. Overall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.
Nanoscience research, which explores the unusual properties of materials at the nanoscale, has led to advancements in medicine, energy, information storage, computing and other fields. At no more than 100 nanometers, nanoparticles are exceedingly small. By comparison, a sheet of paper is about 75,000 nanometers thick.
This study was conducted in a laboratory setting in Orlando, at Nemours Children’s Hospital and the University of Central Florida in cells from children with neuroblastoma, but researchers hope to begin to use these curcumin nanoparticles with micro RNA in animal models to direct the molecule to a tumor site.
Learn more: UCF, Nemours Collaborate to Defeat Difficult-to-Treat Childhood Cancer
The Latest on: Neuroblastoma
[google_news title=”” keyword=”neuroblastoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Littlefield students raise money for cancer foundation; organizer recognized for ‘making a difference’on April 26, 2024 at 12:32 am
Peggy Robison has encouraged students to save up what’s in their piggy banks, and donate it to kids battling cancer.
- Y-mAbs to Present at 2024 ASCO Annual Meetingon April 25, 2024 at 1:11 pm
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...
- Mother's portraits bring son 'back to life'on April 25, 2024 at 7:43 am
A mother whose son died of cancer has said creating "beautiful" yet "sinister" artwork helps "bring him back to life". Artist Joanne Humphreys, 60, from Cheltenham, uses cell images, MRI scans and ...
- Virginia Beach mom started nonprofit to help families dealing with childhood canceron April 25, 2024 at 4:48 am
Crissy Johnson started MomAdvocate Foundation in 2020 to provide support that could have helped her when her son, David, was diagnosed with cancer as a toddler.
- Mum who lost son, 4, to cancer creates artwork to 'bring him back to life'on April 24, 2024 at 7:59 pm
Joanne Humphreys, 60, a professional artist and art teacher from Cheltenham, revealed that her son Graeme was diagnosed with neuroblastoma, a rare form of cancer, in January 1998 when he was just two ...
- A new era for treating high-risk neuroblastoma – research advances to look out for in 2024on April 24, 2024 at 5:50 am
It's an exciting time for research into high-risk neuroblastoma. Over the past year, multiple trials testing new treatments showed promising results, and in 2024, new trials are expected to open to ...
- My brave daughter, 6, beat cancer but now it’s returned and NHS won’t fund her treatment – I’m crushedon April 23, 2024 at 12:34 pm
THE family of a six-year-old girl who beat cancer need help to pay for a last-ditch treatment after it returned. Amelia Kolpa was diagnosed with rare neuroblastoma in the stomach aged two in 2020 ...
- Community Rallies to Fulfill Wishes of 5-Year-Old Battling Stage Four Neuroblastomaon April 23, 2024 at 12:29 am
Nearly one hundred thousand euros collected in a few days to fulfill all the wishes of Sara, the 5-year-old girl from Faenza suffering from stage four neuroblastoma for whom treatment has ...
- A Community Rallies to Fulfill the Wishes of a Young Girl Battling Stage IV Neuroblastomaon April 19, 2024 at 10:51 pm
Sara Cantagalli was 3 years old when she was diagnosed with stage IV neuroblastoma. Since then, she has undergone chemotherapy, but now at the age of 5, she has had to stop treatment because ...
- Neuroblastoma study identifies new subgroups with distinct prognoses and potential vulnerabilities to therapieson April 9, 2024 at 7:00 am
Researchers have identified new variations in neuroblastoma that could lead to a more accurate prognosis and better-targeted treatments for this devastating childhood cancer.
via Google News and Bing News